Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 Inhibitor for Early Neurological Deterioration in Branch Atheromatous Disease
ChiCTR2600130261Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of evolocumab in ischemic stroke and branch atheromatous disease (BAD) (2 arms), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoints: Incidence of Early Neurological Deterioration (END), Incidence of Severe Early Neurological Deterioration (SEND) and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
evolocumab
03
Conditions
ischemic strokebranch atheromatous disease (BAD)
Beyond the preview
Go deeper on ChiCTR2600130261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130261.